Purpose The aim of this study was to evaluate the role of PET/CT and sentinel lymph node (SLN) biopsy in staging high-risk endometrial cancer patients (G2 and deep myometrial invasion, G3, serous clear cell carcinoma or carcinosarcoma) in early clinical stage. Patients and Methods From January 2006 to December 2012, high-risk early-stage endometrial cancer patients performing PET/CT scan followed by surgery (systematic pelvic ± aortic lymphadenectomy) were included. From December 2010, SLN mapping with <sup>99m</sup>Tc-albumin nanocolloid and blue dye cervical injection was included in our clinical practice and additionally performed. Histological findings were used as the reference standard. Results Ninety-three patients were included, of which 22 of 93 had both PET/CT and SLN biopsy. The median number of dissected lymph nodes (LNs) was 28. Nineteen women (20.4%) had pelvic LN metastases; 14 were correctly identified by PET/CT. Among 5 false-negative cases, 3 occurred after the introduction of SLN mapping due to detection of micrometastases by ultrastaging. On overall patient-based analysis, the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of PET/CT for pelvic LN metastases were 73.7%, 98.7%, 93.6%, 93.3%, 93.6%, respectively. Conclusions PET/CT demonstrated moderate sensitivity and high specificity in detecting pelvic LN metastases; its high positive predictive value (93.3%) is useful to refer patients to appropriate debulking surgery. Sentinel LN mapping and histological ultrastaging increased the identification of metastases (incidence, 18.3%-27.3%) not detectable by PET/CT because of its spatial resolution. The combination of both modalities is promising for nodal staging purpose.

Signorelli, M., Crivellaro, C., Buda, A., Guerra, L., Fruscio, R., Elisei, F., et al. (2015). Staging of High-Risk Endometrial Cancer With PET/CT and Sentinel Lymph Node Mapping. CLINICAL NUCLEAR MEDICINE, 40(10), 780-785 [10.1097/RLU.0000000000000852].

Staging of High-Risk Endometrial Cancer With PET/CT and Sentinel Lymph Node Mapping

SIGNORELLI, MAURO
Primo
;
CRIVELLARO, CINZIA
Secondo
;
BUDA, ALESSANDRO ANTONIO;GUERRA, LUCA;FRUSCIO, ROBERT;DOLCI, CARLOTTA;CUZZOCREA, MARCO;MILANI, RODOLFO
Penultimo
;
MESSA, MARIA CRISTINA
Ultimo
2015

Abstract

Purpose The aim of this study was to evaluate the role of PET/CT and sentinel lymph node (SLN) biopsy in staging high-risk endometrial cancer patients (G2 and deep myometrial invasion, G3, serous clear cell carcinoma or carcinosarcoma) in early clinical stage. Patients and Methods From January 2006 to December 2012, high-risk early-stage endometrial cancer patients performing PET/CT scan followed by surgery (systematic pelvic ± aortic lymphadenectomy) were included. From December 2010, SLN mapping with 99mTc-albumin nanocolloid and blue dye cervical injection was included in our clinical practice and additionally performed. Histological findings were used as the reference standard. Results Ninety-three patients were included, of which 22 of 93 had both PET/CT and SLN biopsy. The median number of dissected lymph nodes (LNs) was 28. Nineteen women (20.4%) had pelvic LN metastases; 14 were correctly identified by PET/CT. Among 5 false-negative cases, 3 occurred after the introduction of SLN mapping due to detection of micrometastases by ultrastaging. On overall patient-based analysis, the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of PET/CT for pelvic LN metastases were 73.7%, 98.7%, 93.6%, 93.3%, 93.6%, respectively. Conclusions PET/CT demonstrated moderate sensitivity and high specificity in detecting pelvic LN metastases; its high positive predictive value (93.3%) is useful to refer patients to appropriate debulking surgery. Sentinel LN mapping and histological ultrastaging increased the identification of metastases (incidence, 18.3%-27.3%) not detectable by PET/CT because of its spatial resolution. The combination of both modalities is promising for nodal staging purpose.
Articolo in rivista - Articolo scientifico
endometrial cancer; high risk; lymphadenectomy; PET/CT; sentinel node
English
2015
40
10
780
785
reserved
Signorelli, M., Crivellaro, C., Buda, A., Guerra, L., Fruscio, R., Elisei, F., et al. (2015). Staging of High-Risk Endometrial Cancer With PET/CT and Sentinel Lymph Node Mapping. CLINICAL NUCLEAR MEDICINE, 40(10), 780-785 [10.1097/RLU.0000000000000852].
File in questo prodotto:
File Dimensione Formato  
Staging_of_High_Risk_Endometrial_Cancer_With.3.pdf

Solo gestori archivio

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 485.75 kB
Formato Adobe PDF
485.75 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/88910
Citazioni
  • Scopus 56
  • ???jsp.display-item.citation.isi??? 50
Social impact